Compare Merck & Co., Inc. (MRK) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Roundhill NVDA WeeklyPay ETF — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Roundhill NVDA WeeklyPay ETF trades at $37.11. The key difference: Merck & Co., Inc. pays a 2.29% dividend while Roundhill NVDA WeeklyPay ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| MRK | NVDW | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $156.43 | $52.33 |
52-Week Low | $77.60 | $31.88 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
NVDW (Roundhill NVDA WeeklyPay ETF) trades at $37.60, down 3.22% with a bullish technical signal from moving averages. The ETF provides leveraged exposure to Nvidia with weekly dividend payments, though key valuation ratios remain unavailable. Recent news highlights its high-yield income strategy tied to NVDA's performance, with payouts fluctuating based on underlying stock volatility.
The outlook depends heavily on Nvidia's continued earnings strength and AI market momentum. Key risks include leverage amplification during NVDA downturns and variable dividend sustainability. Investors seeking weekly income from tech exposure may find value, but must monitor NAV erosion risks amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
